Edesa Biotech, Inc. — Form 10-Q summary
Reporting period: Fiscal quarter ended December 31, 2022 (the first quarter of fiscal 2023). Edesa is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-related diseases; it reported no revenue for the quarter.
Financial position and results
- Operating expenses: $2.38 million, down from $5.16 million in the year-earlier quarter. Research and development was $1.36 million versus $3.95 million; general and administrative expense was $1.02 million versus $1.21 million.
- Net loss: $2.33 million, or $0.13 per share, compared with $4.38 million, or $0.33 per share. The prior-year quarter included $0.78 million in reimbursement grant income; none was recorded this quarter. No operating margin is meaningful because the filing reports no revenue.
- Cash flow: $1.79 million used in operations, versus $3.21 million used in the prior-year quarter. Financing provided $2.91 million net, mainly from the November 2022 equity offering. Cash increased $1.18 million during the quarter to $8.27 million.
- Liquidity: Current assets were $9.09 million and current liabilities $1.28 million; management reported working capital of $7.81 million. Total assets were $11.67 million and shareholders’ equity $10.27 million.
- Debt and leases: The balance sheet does not show conventional borrowings. Total liabilities were $1.40 million, including $146,533 in lease liabilities and $44,280 in long-term payables.
- Equity financing and potential dilution: The November private placement issued 2,691,337 common shares and warrants, generating $2.91 million net. At December 31, 6,343,283 warrants were outstanding. After quarter-end and through the filing date, 705,314 shares were issued upon warrant exercises for $0.77 million. The company reported 20,058,665 shares outstanding as of February 9, 2023.
Key changes and developments
- Lower R&D spending, primarily from reduced external clinical-study and drug-manufacturing costs, drove most of the decline in operating expenses and net loss.
- Grant income fell to zero as the Canadian Strategic Innovation Fund reimbursements had been fully received; the filing says the grant-funded clinical activities had been completed.
- In December 2022, the FDA granted Fast Track designation to EB05, which is being studied in ARDS. Edesa said it was enrolling patients in the Phase 3 portion of the study.
- In January 2023, Edesa reported preliminary Phase 2b results for EB01 in chronic allergic contact dermatitis: the 1.0% formulation showed statistically significant improvement over placebo on the primary endpoint and a key secondary endpoint. The 2.0% and 0.2% formulations did not show significant differences from placebo. The company cautioned that results were preliminary and said it was preparing for an FDA End-of-Phase-2 meeting after full analysis.
- Health Canada approved Edesa’s clinical trial application for a future Phase 2 study of EB06 in vitiligo in January 2023. The company was also preparing a U.S. IND for EB07 in systemic sclerosis.
Outlook, risks, and commitments
- Management said it planned to fund operations over the next 12 months with cash on hand, including subsequent warrant-exercise proceeds. It may adjust spending and expects to seek additional financing through equity, grants, debt, licensing, collaborations, or other strategic arrangements. Adequate financing on acceptable terms is not assured; the filing gives no specific revenue or earnings guidance.
- Research and other contractual commitments totaled approximately $2.36 million, including $1.89 million due in fiscal 2023. Separately, license agreements provide for contingent milestone payments of up to $356 million, $18.4 million, and $69.1 million, plus potential royalties or sublicensing payments; these are not presented as current liabilities.
- Risks include clinical and regulatory uncertainty, fluctuating trial and manufacturing costs, and the need for additional capital. Edesa disclosed that a 10% annual change in the Canadian/U.S. exchange rate could affect loss and other comprehensive loss by approximately $0.5 million; it has no currency hedges.
- The company reported no material legal proceedings outside the ordinary course and no material changes to the risk factors in its latest Form 10-K. Management concluded disclosure controls were effective at quarter-end.
Important facts for investors to verify
- Progress, enrollment, and results of the EB05 Phase 3 study, including the regulatory path following Fast Track designation.
- Final analysis of the EB01 Phase 2b study and the outcome of the planned FDA meeting.
- Cash use, clinical and manufacturing commitments, and whether new financing is needed sooner than management expects.
- Warrant exercises, remaining warrant overhang, and resulting share dilution.
- Milestone, royalty, and sublicensing obligations under the product-license agreements.